Elan (ELN) Will Be a Buyer Not a Seller, Unless Offer Nears $20/Sh - Jefferies
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/25/2024
- S&P 500 ends higher as markets weigh rising yields, upbeat corporate results
- Meta Platforms reports softer Q2 revenue guidance on plans to boost spending on AI
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Equities mixed as investors eye earnings; yen on intervention watch
- ServiceNow (NOW) stock falls as refreshed subscription outlook trails estimates
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Hasbro (HAS) brand strength sees earnings top expectations
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Crude Inventory Declined 6.4 Million Barrels Last Week
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
Leerink Swann Upgrades Elan Corp (ELN) to Market Perform
February 25, 2013 9:20 AM ESTLeerink Swann upgraded Elan Corp (NYSE: ELN) from Underperform to Market Perform.
For an analyst ratings summary and ratings history on Elan Corp click here. For more ratings news on Elan Corp click here.
Shares of Elan Corp closed at $10.60 yesterday, with a 52 week range of $9.37-$15.27.... More
Elan Corp (ELN) Up 9% on Takeover Bid
February 25, 2013 6:55 AM ESTElan Corp (NYSE: ELN) is trading up 9 percent to $11.60/share early Monday after receiving an $11/share takeover bid from Royalty Pharma.... More
RP Management Bids $11/Share for Elan Corp (ELN)
February 25, 2013 6:06 AM ESTRP Management, LLC ("Royalty Pharma") today announces that contact was made on Monday February 18, 2013 with the Chairman of the Board of Elan Corporation, plc (NYSE: ELN) ("Elan"), followed by a meeting then taking place on Wednesday February 20, 2013, at which an indicative proposal was made to acquire the entire issued and to be issued share capital of Elan (the "Proposal").
Royalty Pharma is proposing, on an indicative basis, to make an offer for Elan (the "Possible Offer") of US$11[1] for every Elan Share and every Elan ADS.
While Royalty... More
